Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 4/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26813651 | 0.90 | CPB2 (0.45) | CPB2MEN1KMT2AKDM5AKDM5B | |
| SCHEMBL5726708 | 0.89 | CPB2 (0.45) | CPB2MEN1KMT2ACPB1SMYD3 | |
| SCHEMBL7425205 | 0.86 | SMYD3 (0.50) | CPB2MEN1KMT2ASMYD3GRM2 | |
| SCHEMBL15775548 | 0.85 | MEN1 (0.43) | CPB2MEN1KMT2ACPB1SMYD3 | |
| SCHEMBL28934829 | 0.85 | NOTUM (0.49) | CPB2MEN1KMT2AKDM5AKDM5B | |
| SCHEMBL21361934 | 0.85 | MEN1 (0.43) | CPB2MEN1KMT2ASMYD3GRM2 | |
| SCHEMBL20139133 | 0.84 | MEN1 (0.42) | CPB2MEN1KMT2ASMYD3GRM2 | |
| SCHEMBL26813648 | 0.84 | CPB2 (0.42) | CPB2MEN1KMT2ACPB1SMYD3 | |
| SCHEMBL28579686 | 0.83 | MEN1 (0.41) | CPB2MEN1KMT2ACPB1SMYD3 | |
| SCHEMBL26641301 | 0.83 | KDM5A (0.47) | MEN1KMT2AKDM5AKDM5BSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2019-06-18 | — | — | US | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-1898903-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008317-B2 | Inhibitors of akt activtiy | MERCK SHARP & DOHME CORP. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222321-A1 | Inhibitors of akt activtiy | MERCK SHARP & DOHME LLC | 2010-09-02 | — | — | US | disclosed |
| EP-1898903-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006135627-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322143-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | CPB2 465/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-20100222321-A1 | Inhibitors of akt activtiy | PIK3CA, PIK3CD, INPP5D | CPB2 2627/4885MEN1 1060/4885KMT2A 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.